Myriad Genetics Inc
XETRA:MYD
Myriad Genetics Inc
XETRA:MYD
Price:
26.72
EUR
1.98%
Market Closed
Market Cap:
€2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Myriad Genetics Inc
XETRA:MYD
|
US |
|
M
|
Merck & Co Inc
PAR:MRK
|
US |
|
S
|
Synergy Grid and Development Phils Inc
XPHS:SGP
|
PH |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
US |
|
Heliogen Inc
OTC:HLGN
|
US |
|
Mindteck (India) Ltd
NSE:MINDTECK
|
IN |
|
S
|
Suraj Estate Developers Ltd
NSE:SURAJEST
|
IN |
|
N
|
Newmont Corporation
ASX:NEM
|
US |
|
B
|
Bloober Team SA
WSE:BLO
|
PL |
|
Harley-Davidson Inc
NYSE:HOG
|
US |
|
A
|
Alibaba Group Holding Ltd
HKEX:9988
|
CN |
|
F
|
Fluidra SA
XBER:4F1
|
ES |
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
US |
|
S
|
Sino Biopharmaceutical Ltd
OTC:SBHMY
|
HK |
|
Physicians Realty Trust
NYSE:DOC
|
US |
|
R
|
RomReal Ltd
OSE:ROM
|
BM |
|
Juno Minerals Ltd
OTC:JNOMF
|
AU |
|
Strategem Capital Corp
XTSX:SGE
|
CA |
|
S
|
Sbf AG
F:CY1K
|
DE |
|
ONEOK Inc
NYSE:OKE
|
US |
|
Z
|
Zeder Investments Ltd
JSE:ZED
|
ZA |
Multiples-Based Value
The Multiples-Based Value of one
MYD
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 26.72 EUR,
Myriad Genetics Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MYD Multiples-Based Value
LOCKED
Multiples Across Competitors
MYD Competitors Multiples
Myriad Genetics Inc Competitors
Myriad Genetics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Myriad Genetics Inc
XETRA:MYD
|
444.1m EUR | 0.5 | -1.2 | -29.5 | -6.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
